Prashant Kapoor, MD
Hematology · Rochester, MNNPI 1487671152
Payments from drug & device makers
Across 339 payments — averaging $22,491 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$1.4M
- Amgen$1.4M
- Regeneron$1.2M
- Sanofi US Services Inc.$1.1M
- AbbVie$687K
- Takeda Pharmaceuticals U.S.A., Inc.$664K
- plus $1.1M from 16 others
Across 21 payments — averaging $15,353 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ichnos Glenmark Innovation Inc$321K
- Regeneron$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 9 | $1,428,793 |
| Amgen | 30 | $1,421,796 |
| Regeneron | 57 | $1,242,362 |
| Sanofi US Services Inc. | 48 | $1,104,360 |
| AbbVie | 65 | $686,976 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $664,370 |
| Karyopharm Therapeutics Inc. | 10 | $586,624 |
| GSK | 43 | $229,874 |
| Beigene, Ltd. | 8 | $81,215 |
| Beone Medicines Ltd. | 7 | $55,732 |
| Sanofi | 17 | $46,715 |
| E.r. Squibb & Sons, L.L.C. | 9 | $34,406 |
| Takeda | 2 | $19,714 |
| Beigene Switzerland GmbH | 8 | $8,376 |
| Pharmacyclics LLC, An Abbvie Company | 8 | $3,340 |
| Gilead | 1 | $2,700 |
| Janssen Scientific Affairs, LLC | 6 | $2,394 |
| Genentech, Inc. | 1 | $1,875 |
| Beigene USA, Inc. | 1 | $1,625 |
| AstraZeneca | 1 | $1,028 |
| Legend Biotech USA Inc. | 3 | $104 |
| EUSA Pharma (US) LLC | 1 | $22 |
How this compares
$7,624,402 in reported general payments places this provider in the 95th percentile of 111 hematology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Rochester
- Sameer ParikhRochester$44.6M
- Shaji KumarRochester$29.6M
- Lindsey RoekerRochester$9.7M
- Yi LinRochester$9.2M
- Grzegorz NowakowskiRochester$9.1M
- Patrick JohnstonRochester$7.3M
- Mark LitzowRochester$7M
- Jose Villasboas BisnetoRochester$5.5M
- Stephen AnsellRochester$5.1M
- Angela DispenzieriRochester$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.